Fuso Pharmaceutical Industries,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

The company reported a significant increase in operating and net income relative to revenue growth, supported by operating leverage from reductions in selling, general and administrative expenses. Revenue was ¥160.5B (+3.5% YoY), operating income was ¥9.7B (+63.0%), ordinary income was ¥9.1B (+40.9%), and net income was ¥6.4B (+39.0%). The gross margin was 26.2%, broadly in line with the previous year, while the improvement in the SG&A ratio (20.1%, approximately -2.4pt YoY) was the primary driver of earnings growth.

Factors Affecting Results

【Revenue】Revenue increased 3.5% YoY to ¥160.5B. Although segment information was not disclosed, progress against the full-year forecast (¥632.0B, YoY +1.4%) was 25.4%, a standard level.

【Profit and Loss】Operating income increased significantly by 63.0% YoY to ¥9.7B, and the operating margin improved by +2.2pt from 3.8% in the previous year to 6.1%. While the cost of sales ratio was broadly flat, SG&A expenses declined 3.5% to ¥32.2B, reducing the SG&A ratio to 20.1%, which was the primary driver of earnings growth. In non-operating items, interest expense increased from ¥0.7B to ¥1.0B, increasing the interest burden; however, ordinary income rose 40.9% to ¥9.1B, as the improvement at the operating level absorbed this impact. Net income was ¥6.4B (+39.0% YoY), reflecting the tax burden (corporate income taxes and other taxes of ¥2.7B and an effective tax rate of approximately 29.4%). The company reported higher revenue and higher earnings.

Key Financial Indicators

【Profitability】The operating margin improved to 6.1% from 3.8% in the previous year, while the net profit margin also increased to 4.0%. The gross margin was 26.2%, broadly in line with the previous year, indicating that the improvement in profitability was primarily attributable to SG&A efficiency.【Cash Flow Quality】Cash and deposits were ¥45.7B, slightly down from ¥46.5B in the previous year, while accounts receivable of ¥237.0B and inventories of ¥133.3B represented substantial asset balances.【Investment Efficiency】ROE was 1.8%, a level explained by the combination of the net profit margin, total asset turnover (approximately 0.18x), and financial leverage (approximately 2.45x).【Financial Soundness】The equity ratio was 40.9%, improving from 38.8% in the previous year. Total assets declined to ¥874.7B from ¥903.2B in the previous year, while net assets increased to ¥357.5B.

Cash Flow Analysis

As the cash flow statement was not disclosed, cash flow trends are assessed based on changes in the balance sheet. Cash and deposits were ¥45.7B, a slight decrease from ¥46.5B in the previous year. Short-term borrowings declined YoY, moving from ¥244.9B to around ¥244.9B, although interest-bearing debt remains heavily weighted toward short-term obligations. Accounts receivable declined from ¥237.0B to the ¥269.0B range, while inventories were broadly flat, moving from ¥133.3B to the ¥135.3B range; accordingly, the scope for working capital reduction is limited. While total assets contracted from ¥874.7B to ¥903.2B, net assets increased from ¥357.5B to ¥350.6B, indicating a slight improvement in capital efficiency.

Earnings Quality

There appears to have been no impact from extraordinary gains or losses on earnings for the current period, which can therefore be viewed as having arisen from recurring business activities. Non-operating income was ¥1.9B, equivalent to 1.2% of revenue, indicating a low degree of dependence, while interest expense of ¥1.0B accounted for the increase in interest burden among non-operating expenses of ¥2.5B. Operating income of ¥9.7B declined stepwise to ordinary income of ¥9.1B and net income of ¥6.4B due to non-operating gains and losses and the tax burden; this structure was not materially different from the previous year. The fact that SG&A reductions were the primary driver of earnings growth indicates that cost efficiency contributed more than a qualitative transformation in the earnings structure, and its sustainability will depend on future SG&A trends.

Earnings Forecast and Guidance

The full-year forecast is revenue of ¥632.0B (YoY +1.4%), operating income of ¥20.0B (YoY -24.2%), ordinary income of ¥14.0B (YoY -40.4%), and net income of ¥13.0B (YoY -35.4%). Q1 progress was approximately standard at 25.4% for revenue, while profit items were significantly ahead of schedule, at 48.6% for operating income, 65.1% for ordinary income, and 49.4% for net income. Given that the full-year forecast assumes lower earnings YoY, the significant earnings growth in Q1 suggests either a concentration in the first half or upside potential relative to the cautious full-year outlook.

Shareholder Returns

The full-year dividend forecast is ¥90 per share, with no revisions to the dividend forecast during the current quarter. The payout ratio against the full-year forecast EPS of ¥152.25 is approximately 59.1%. As the dividend was ¥45 in the previous year, the full-year forecast of ¥90 represents a plan to increase the annualized dividend.

Risk Factors

1. Working capital efficiency risk: Accounts receivable of ¥237.0B and inventories of ¥133.3B represent substantial asset balances, and delays in collections or inventory turnover could constrain cash generation.

2. Refinancing risk associated with reliance on short-term funding: Short-term borrowings were ¥244.9B, compared with long-term borrowings of ¥18.2B, indicating that the majority of interest-bearing debt is concentrated in short-term obligations. If interest rates rise, interest expense (¥1.0B in the current period versus ¥0.7B in the previous year) could increase further.

3. Sustainability risk of SG&A efficiency gains: Earnings growth in the current period depended heavily on the improvement in the SG&A ratio (20.1% versus 22.5% in the previous year); if cost controls are reversed, the improvement in profitability could reverse.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The company's profitability is significantly below the industry median, placing it in the low-profitability group within the pharmaceutical industry.

Growth and Capital Efficiency

The revenue growth rate also remains below the industry median, indicating that top-line growth is relatively modest within the industry.

※Source: Compiled by the Company

Key Points in the Results

1. Earnings growth in the current period was primarily driven by a significant improvement in the SG&A ratio (-2.4pt), while the gross margin was broadly flat. This structure reflects the substantial impact of cost controls rather than an improvement in product mix, making the monitoring of SG&A trends in subsequent quarters key to assessing sustainability.

2. While the full-year forecast assumes lower earnings YoY, progress for profit items in Q1 was significantly ahead of schedule at 48–65%. This contrast suggests either conservatism in the full-year outlook or the possibility of expense normalization and convergence in profitability toward the second half.

3. Short-term borrowings account for the majority of interest-bearing debt, and interest expense increased by ¥0.3B from the previous year. Together with substantial working capital balances (accounts receivable and inventories), this indicates relatively high sensitivity to the interest-rate environment and the timing of funding requirements.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,448–¥3,643 at ±1% for the cost of equity, and ¥3,523–¥3,557 at ±0.1 for ω.

Notes:

• Because progress of net income against the full-year forecast (49%) exceeds the standard level (25%), forecast EPS has been adjusted upward within an upper limit of +10% (because companies with progress ahead of schedule tend to outperform forecasts; adjustments may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated at a somewhat high level.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest-rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee the future share price.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional where necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong earnings quarter for Fuso Pharmaceutical Industries, with modest sales growth translating into materially faster operating and net-profit growth. Revenue increased 3.5% year on year to ¥16.05bn. Operating income rose 63.0% to ¥0.97bn, substantially outpacing revenue growth. Ordinary income increased 40.9% to ¥0.91bn. Net income grew 39.0% to ¥0.64bn, and EPS was ¥75.30. The gross margin was broadly stable at 26.2%, down approximately 15bp from 26.3% in the prior-year quarter. The principal driver of the earnings improvement was SG&A discipline: SG&A declined 7.4% year on year to ¥3.23bn despite higher sales. Consequently, the SG&A-to-sales ratio improved by roughly 236bp to 20.1%. Operating margin expanded by approximately 222bp to 6.1%, while net margin improved by roughly 102bp to 4.0%. The tax burden was normal at 70.5%, equivalent to an effective tax rate of 29.4%. Interest coverage of 9.35x remains sound, although interest expense rose 48.6% to ¥0.10bn. The balance sheet improved modestly, with total equity rising 2.0% year on year to ¥35.75bn and short-term borrowings declining 7.3% to ¥24.49bn. However, the funding profile remains a central issue because 93.1% of interest-bearing debt is short term and cash covers only 0.19x of short-term debt. Working-capital intensity is also high, as receivable days of 135 days, inventory days of 122 days and a 223-day cash-conversion cycle constrain liquidity flexibility. Q1 progress against full-year guidance is unusually high for profits, suggesting either pronounced first-quarter seasonality or a conservative full-year plan. Full-year company guidance nevertheless calls for operating income to decline 24.2% and net income to decline 35.4% year on year, so sustaining Q1's SG&A efficiency and gross-margin resilience is critical to the outlook.

Profitability Analysis

The reported annualized DuPont ROE is 7.2%, comprising a 4.0% net profit margin, 0.734x asset turnover and 2.45x financial leverage. Net margin is the principal profitability constraint: although it improved from approximately 3.0% in the prior-year quarter, it remains below the 5% level generally associated with stronger earnings quality. The quarter's largest positive operating change was margin expansion rather than revenue growth. Gross profit increased 2.9% to ¥4.20bn, slightly slower than sales, causing gross margin to edge down about 15bp to 26.2%. In contrast, SG&A fell from ¥3.48bn to ¥3.23bn, reducing the SG&A ratio to 20.1% from 22.5%. This SG&A leverage produced a 63.0% increase in operating income and lifted the operating margin to 6.1% from 3.8%. The extended DuPont interest burden of 0.937 indicates that financing costs reduce EBIT by a manageable, but visible, amount before tax. The 2.45x financial-leverage component supports ROE, meaning the 7.2% annualized ROE should not be viewed solely as a reflection of operating asset productivity. The capital-efficiency alert is therefore significant: reported ROIC of 4.8% is below the 5% warning threshold, indicating returns on the operating capital base remain modest despite the Q1 profit recovery. The sustainability of the quarterly margin improvement depends on whether the lower SG&A run rate can persist while preserving product promotion, quality assurance and manufacturing support capabilities.

Growth Assessment

Revenue growth of 3.5% was positive but modest, while profit growth was primarily cost-leverage driven. The stable gross margin indicates that the Q1 improvement was not dependent on a major pricing or product-mix uplift. Accounts receivable declined 11.9% year on year to ¥23.70bn, while finished-goods inventory declined 1.4% to ¥13.33bn; these movements are constructive in balance-sheet terms but working-capital days remain elevated relative to sales. Raw-material inventory increased 16.1% to ¥2.42bn, which warrants monitoring for procurement-cost or supply-chain effects. Against FY2027 guidance, Q1 revenue represents 25.4% of the ¥63.20bn full-year target, broadly consistent with the standard 25% first-quarter run rate. Q1 operating income represents 48.6% of the ¥2.00bn full-year forecast, 23.6 percentage points above the standard 25% progress rate. Q1 net income represents 49.4% of the ¥1.30bn full-year forecast, 24.4 percentage points above the standard pace. This divergence is notable because management's full-year outlook embeds a 24.2% decline in operating income and a 35.4% decline in net income year on year. The implied second-half earnings profile therefore requires either material cost increases, margin pressure, or an intentionally conservative forecast assumption. As a pharmaceutical manufacturer, the company remains exposed to reimbursement-price revisions, tender and generic competition, raw-material procurement costs, and stringent manufacturing-quality requirements. Revenue durability should be assessed through subsequent-quarter sales momentum and whether the Q1 SG&A ratio remains near 20%.

Financial Health

Liquidity is adequate on a headline current-ratio basis but tight when assessed against the debt maturity structure. The current ratio is 1.12x, above the 1.0x warning threshold, supported by working capital of ¥5.91bn. The quick ratio is only 0.85x, however, indicating that current obligations are not fully covered by cash and receivables alone. Current liabilities of ¥48.18bn account for 93.2% of total liabilities, compared with current assets of ¥54.09bn. Short-term loans are ¥24.49bn, equal to 28.0% of total assets and 50.8% of current liabilities. This creates a material maturity mismatch risk because the company relies on continued refinancing of short-term facilities rather than internally held cash. The REFINANCING_RISK alert is warranted: 93.1% of ¥26.31bn interest-bearing debt is short term, well above the 40% alert threshold. Its root cause is the concentration of borrowings in short-term loans rather than long-term debt, which is only ¥1.82bn. The impact is that changes in bank credit availability or borrowing rates could affect both liquidity and future earnings. The LIQUIDITY_STRESS alert is also warranted because cash and deposits of ¥4.57bn cover just 0.19x of short-term borrowings, below the 0.5x threshold. This profile is more demanding than the current ratio alone suggests, particularly given the long working-capital cycle. Debt-to-capital is 42.4%, modestly above the 40% investment-grade reference point, while the reported D/E ratio of 1.45x is elevated but below the 2.0x aggressive-leverage warning level. Interest coverage of 9.35x provides a meaningful near-term buffer, but its preservation depends on operating profit and refinancing costs. The balance sheet is primarily tangible, with property, plant and equipment of ¥22.17bn and intangible assets equal to only 1.5% of total assets, limiting acquisition-related intangible-asset risk.

Notable B/S Changes

Provision for bonuses: -¥0.45bn (-48.4%) year on year to ¥0.48bn - reduced accrued personnel-cost obligation supported the decline in current liabilities, though future-period expense normalization should be monitored. Electronically recorded obligations: -¥1.16bn (-38.6%) year on year to ¥1.85bn - lower electronic payables contributed to the reduction in current liabilities and may reduce supplier-financing flexibility. Short-term loans: -¥2.12bn (-7.3%) year on year to ¥24.49bn - leverage has reduced, but short-term funding still represents 93.1% of interest-bearing debt and remains the principal refinancing risk. Valuation difference on securities: +¥0.44bn (+15.9%) year on year to ¥3.17bn - improved valuation reserves supported equity, although this is market-value sensitive rather than operating earnings.

Cash Flow Quality

Working-capital conversion is the principal cash-flow-quality concern. The HIGH_RECEIVABLE_DAYS alert reflects DSO of 135 days, far above the 60-day reference threshold. Its root cause is the ¥23.70bn receivables balance relative to quarterly sales, indicating a large amount of capital is tied up between invoicing and collection. This can be structurally influenced by pharmaceutical distribution and institutional-customer payment terms, but the level restricts financial flexibility and increases collection-timing sensitivity. The HIGH_INVENTORY_DAYS alert of 122 days is also material, exceeding the 90-day threshold. A second inventory-days alert of 103 days likewise exceeds its 60-day benchmark, confirming that inventory intensity is elevated under both reported measurement bases. Finished goods of ¥13.33bn comprise virtually all reported inventory, making demand forecasting, shelf-life management and inventory obsolescence important operating considerations. The LONG_CCC alert of 223 days, against a 120-day threshold, combines the slow receivables collection and elevated inventory holding period into a substantial cash-conversion burden. The impact of these alerts is higher reliance on short-term borrowing and greater sensitivity to any slowdown in customer collections or inventory turnover. Receivables and finished goods both declined year on year, which is directionally favorable, but the reported day metrics remain high and require sustained improvement. Cash-flow resilience should be assessed through future changes in receivables, finished-goods stock, short-term loans and cash balances.

Dividend Sustainability

The FY2027 full-year dividend forecast is ¥90 per share, unchanged from the stated policy revision status. Based on forecast EPS of ¥152.25, the implied dividend payout ratio is 59.1%. This is just within the 60% sustainability reference level and leaves a limited earnings buffer if the full-year forecast is not achieved. Q1 EPS of ¥75.30 represents 49.5% of full-year forecast EPS, reinforcing that the forecast assumes substantially weaker earnings over the remaining quarters. The company has ¥14.14bn of retained earnings, which provides an equity reserve, but liquidity management is more relevant than accounting reserves given the short-term-debt concentration. Dividend sustainability will depend on maintaining profitability, collections discipline and access to short-term refinancing. No share-buyback information is provided, so the assessment is limited to the dividend payout ratio rather than a total return ratio. The absence of a dividend forecast revision alongside a profit forecast that declines year on year suggests management currently intends to maintain shareholder distributions through an expected earnings normalization.

Risk Assessment

Business risks include Pharmaceutical reimbursement-price revisions, generic competition and tender pricing could pressure the 26.2% gross margin and reverse the Q1 operating-margin recovery., Manufacturing quality, regulatory compliance, product supply continuity and raw-material sourcing are material risks for a company with ¥22.17bn of PPE and ¥13.33bn of finished-goods inventory., The CAPITAL_EFFICIENCY alert is material: annualized ROIC of 4.8% is below 5%, indicating that operating capital is not yet producing robust returns despite the Q1 earnings rebound., High finished-goods inventory exposes the company to demand-forecast, shelf-life and obsolescence risk if sales momentum weakens..

Financial risks include The REFINANCING_RISK alert is high priority: 93.1% of interest-bearing debt is short term, creating dependence on continued bank refinancing., The LIQUIDITY_STRESS alert is high priority: cash/short-term debt is only 0.19x, and the 0.85x quick ratio shows limited immediately liquid coverage of current obligations., The HIGH_RECEIVABLE_DAYS alert is significant: DSO of 135 days delays conversion of reported sales into cash and increases exposure to collection timing., The HIGH_INVENTORY_DAYS alerts of 122 days and 103 days indicate working-capital intensity above relevant thresholds., The LONG_CCC alert of 223 days compounds receivables and inventory risk, increasing reliance on short-term funding., Interest expense increased to ¥0.10bn from ¥0.07bn, so higher refinancing rates could dilute ordinary income despite current 9.35x interest coverage..

Key concerns include Likelihood and impact are highest for short-term refinancing and working-capital management because both are directly linked: slow cash conversion makes the company more reliant on short-term loans., The FY2027 plan implies profits materially below the Q1 annualized run rate; the potential normalization of SG&A, pricing, or gross margin is a key earnings-risk factor., The Q1 margin improvement was driven mainly by lower SG&A rather than stronger gross margin, which may be less durable if commercial, quality-control or operating costs normalize., ROIC below 5% limits value creation and reduces the cushion against higher funding costs or future industry pricing pressure..

Investment Implications

Key takeaways include Q1 operating income rose 63.0% year on year to ¥0.97bn, driven principally by a 236bp improvement in the SG&A ratio., Gross margin was stable rather than expanding, making cost discipline the key source of the quarter's earnings leverage., Q1 operating-income and net-income progress of 48.6% and 49.4%, respectively, is substantially ahead of the normal 25% first-quarter pace relative to full-year guidance., Short-term borrowings of ¥24.49bn, a 0.19x cash/short-term-debt ratio and a 223-day cash-conversion cycle are the central balance-sheet constraints., The forecast ¥90 DPS implies a 59.1% dividend payout ratio based on forecast EPS, leaving only a modest earnings cushion..

Metrics to watch include Operating margin and SG&A-to-sales ratio, particularly whether the Q1 6.1% operating margin and 20.1% SG&A ratio can be sustained., Receivable days, inventory days and the cash-conversion cycle., Short-term loan balance, cash/short-term-debt coverage and refinancing terms., Gross-margin response to reimbursement, tender pricing, product mix and raw-material costs., Progress versus the ¥63.20bn sales, ¥2.00bn operating-income and ¥1.30bn net-income full-year forecasts., ROIC recovery from the reported 4.8% level..

Regarding relative positioning, The company shows a meaningful Q1 earnings rebound and stable gross profitability, but its 6.1% operating margin, 4.0% net margin, 7.2% annualized ROE and 4.8% ROIC remain below stronger profitability benchmarks. Relative financial positioning is constrained by a short-term-debt-heavy funding model and unusually long working-capital conversion, despite adequate interest coverage and a current ratio above 1.0x.